AbbVie (ABBV) Stock: Why Shares Are Falling Despite Earnings Beat and Strong 2026 Guidance

TLDR AbbVie reported Q4 adjusted earnings of $2.71 per share, beating analyst expectations of $2.65 Revenue reached $16.6 billion in the quarter, surpassing the $16.4 billion estimate 2026 adjusted earnings guidance of $14.37 to $14.57 per share tops consensus view of $14.27 Oncology revenue dropped 2.5% and aesthetics revenue fell 1.2% on an operational basis [...]

The post AbbVie (ABBV) Stock: Why Shares Are Falling Despite Earnings Beat and Strong 2026 Guidance appeared first on Blockonomi.